Cargando…

Investigation of Paraoxonase-1 Genotype and Enzyme-Kinetic Parameters in the Context of Cognitive Impairment in Parkinson’s Disease

Cognitive impairment is a common non-motor symptom of Parkinson’s disease (PD), which often progresses to PD dementia. PD patients with and without dementia may differ in certain biochemical parameters, which could thus be used as biomarkers for PD dementia. The enzyme paraoxonase 1 (PON1) has previ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrič, Boštjan, Redenšek Trampuž, Sara, Dolžan, Vita, Gregorič Kramberger, Milica, Trošt, Maja, Maraković, Nikola, Goličnik, Marko, Bavec, Aljoša
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952446/ https://www.ncbi.nlm.nih.gov/pubmed/36829958 http://dx.doi.org/10.3390/antiox12020399

Ejemplares similares

The Removal of Time–Concentration Data Points from Progress Curves Improves the Determination of K(m): The Example of Paraoxonase 1
por: Petrič, Boštjan, et al.
Publicado: (2022)

Evaluation of the paraoxonase-1 kinetic parameters of the lactonase activity by nonlinear fit of progress curves
por: Goličnik, Marko, et al.
Publicado: (2019)

The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3
por: Taler-Verčič, Ajda, et al.
Publicado: (2020)

Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
por: Bosak, Anita, et al.
Publicado: (2020)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?
por: Redenšek, Sara, et al.
Publicado: (2017)

A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease
por: Petrič, Boštjan, et al.
Publicado: (2021)

Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode
por: Pjevac, Milica, et al.
Publicado: (2023)

Serotonin-Related Functional Genetic Variants Affect the Occurrence of Psychiatric and Motor Adverse Events of Dopaminergic Treatment in Parkinson’s Disease: A Retrospective Cohort Study
por: Redenšek, Sara, et al.
Publicado: (2022)

Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson’s Disease
por: Redenšek, Sara, et al.
Publicado: (2020)

Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinson’s Disease and Dopaminergic Treatment Adverse Events
por: Redenšek, Sara, et al.
Publicado: (2022)

Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature
por: Redenšek Trampuž, Sara, et al.
Publicado: (2023)

Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson’s Disease
por: Levstek, Tina, et al.
Publicado: (2021)

Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review
por: Tsermpini, Evangelia Eirini, et al.
Publicado: (2022)

Genetic Polymorphisms in Oxidative Stress and Inflammatory Pathways as Potential Biomarkers in Alzheimer’s Disease and Dementia
por: Vogrinc, David, et al.
Publicado: (2023)

The Association of Selected GWAS Reported AD Risk Loci with CSF Biomarker Levels and Cognitive Decline in Slovenian Patients
por: Vogrinc, David, et al.
Publicado: (2023)

Nanoscale Bilirubin Analysis in Translational Research and Precision Medicine by the Recombinant Protein HUG
por: Sist, Paola, et al.
Publicado: (2023)

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms
por: Redenšek, Sara, et al.
Publicado: (2018)

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies
por: Tsermpini, Evangelia Eirini, et al.
Publicado: (2022)

Functional Characterization of N-Terminally GFP-Tagged GLP-1 Receptor
por: Bavec, Aljoša, et al.
Publicado: (2009)

Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma
por: Petric, Rok, et al.
Publicado: (2016)

Cost of Diagnosing and Treating Cognitive Complaints: One-year Cost-evaluation Study in a Patient Cohort from a Slovenian Memory Clinic
por: Županič, Eva, et al.
Publicado: (2022)

Paraoxonase/MCS.
por: Rowat, S C
Publicado: (1999)

Introduction to Paraoxonases
por: Aviram, Michael
Publicado: (2012)

The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids
por: Trampuž, Sara Redenšek, et al.
Publicado: (2023)

Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics
por: Pavăl, Denis, et al.
Publicado: (2018)

Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial
por: Strojan, Primoz, et al.
Publicado: (2023)

Human paraoxonase 2
por: Porntadavity, Sureerut, et al.
Publicado: (2010)

Paraoxonase 1 and atherosclerosis
por: Durrington, Paul N., et al.
Publicado: (2023)

Lead Exposure Is Associated with Decreased Serum Paraoxonase 1 (PON1) Activity and Genotypes
por: Li, Wan-Fen, et al.
Publicado: (2006)

Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage
por: Goricar, Katja, et al.
Publicado: (2012)

Copper Deficiency, Lead, and Paraoxonase
por: Klevay, Leslie M.
Publicado: (2007)

Solubilization and Humanization of Paraoxonase-1
por: Sarkar, Mohosin, et al.
Publicado: (2012)

Misconceptions about paraoxonase-1
por: Mackness, Michael, et al.
Publicado: (2021)

Paraoxonases at the Heart of Neurological Disorders
por: Khalaf, Fatimah K., et al.
Publicado: (2023)

Paraoxonase/Arylesterase Activity of Serum Paraoxonase-1 and Schizophrenia: A Systematic Review and Meta-Analysis
por: Zinellu, Angelo, et al.
Publicado: (2023)

High Incidence of Sporadic Creutzfeldt-Jakob Disease in Slovenia in 2015: A Case Series
por: Rus, Tomaž, et al.
Publicado: (2018)

Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer
por: Devarajan, Asokan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kqkpda2ds0ftuv46832k6ul30i